Grifols (GRFS) Other Non Operating Income (2009 - 2018)
Grifols' (GRFS) quarterly Other Non Operating Income came in at -$10.7 million in Q2 2018, down 169.64% YoY from $15.4 million in Q2 2017, and down 169.64% on a QoQ basis from $15.4 million in Q2 2017.
Grifols (GRFS) Other Non Operating Income (2009 - 2018) Analysis & Trends
Grifols (GRFS) has 10 years of Other Non Operating Income data on file, last reported at -$10.7 million in Q2 2018.
- Quarterly Other Non Operating Income fell 169.64% year-over-year to -$10.7 million in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $12.7 million (down 58.09% YoY) and the FY2025 annual result came in at -$64.0 million, changed 0.15% from the prior year.
- Other Non Operating Income retreated to -$10.7 million in Q2 2018, from $15.4 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $23.1 million in Q4 2014 to a low of -$31.5 million in Q1 2014.
- A 5-year average of -$4.8 million and a median of -$953337.4 in 2016 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 2774.93% in 2014, down 531.08% in 2014.
- Tracing GRFS's Other Non Operating Income over 5 years: stood at $23.1 million in 2014, then plunged by 157.64% to -$13.3 million in 2015, then soared by 152.42% to $7.0 million in 2016, then soared by 120.93% to $15.4 million in 2017, then sank by 169.64% to -$10.7 million in 2018.
- The last three Other Non Operating Income figures came in at -$10.7 million (Q2 2018), $15.4 million (Q2 2017), and $7.0 million (Q4 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | -10.73 Mn |
| Jun 30, 2017 | 15.41 Mn |
| Dec 31, 2016 | 6.98 Mn |
| Sep 30, 2016 | 1.06 Mn |
| Jun 30, 2016 | 6.90 Mn |
| Mar 31, 2016 | -2.97 Mn |
| Dec 31, 2015 | -13.31 Mn |
| Sep 30, 2015 | 4.22 Mn |
| Jun 30, 2015 | 2.15 Mn |
| Mar 31, 2015 | -12.85 Mn |
| Dec 31, 2014 | 23.09 Mn |
| Sep 30, 2014 | -25.62 Mn |
| Jun 30, 2014 | -29.84 Mn |
| Mar 31, 2014 | -31.53 Mn |
| Dec 31, 2013 | 803,042.84 |
| Sep 30, 2013 | 5.94 Mn |
| Jun 30, 2013 | -35.64 Mn |
| Mar 31, 2013 | -41.39 Mn |
| Dec 31, 2012 | 1.35 Mn |
| Sep 30, 2012 | -43.52 Mn |